The Total number of records shown on this page is 10. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4646	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (0.5 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result87% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4647	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (0.5 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result80% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4648	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (0.5 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result56% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4649	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (1.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result74% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4650	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (1.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result79% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4651	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (1.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result56% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4652	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (3.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result59% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4653	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (3.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result60% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4654	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (3.0 micromolar/litre)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Louis university	Origin of cell lineCotton rat tumor cell line	Cell lineLCRT	Concentration of cell line1.0E+5 cells per ml	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell viablity after 2 days, additive effect	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103
IDOV_4655	Virus nameBovine herpesvirus	Virus strainBHV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 5-AZa (2mg/kg) intraperitoneal single dose	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCR mice xenograft for LCRT cells (5.0E+5)	In-vivo virus concentration5.0E+6 pfu for 5 days	In-vivo toxicityNA	In-vivo resultCombination therapy results in 3/8 animals with delayed growth	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119103